Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Terminated 2Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Papillary renal cell carcinoma, sporadic 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Basal Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Nivolumab 28pembrolizumab 24cabozantinib 23Ipilimumab 18Specimen Handling 13Magnetic Resonance Spectroscopy 13Axitinib 12lenvatinib 10Radiosurgery 9belzutifan 8atezolizumab 6CTLA-4 Antigen 6Biopsy 6cemiplimab 5Radiotherapy 5Bevacizumab 5toripalimab 4Everolimus 4Blood Specimen Collection 4avelumab 3aldesleukin 3X-Rays 3Sunitinib 3Standard of Care 3Paclitaxel 3zimberelimab 2trastuzumab deruxtecan 2tivozanib 2spartalizumab 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Renal Cell × Erlotinib Hydrochloride × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡